# A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis

> **NCT01609283** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 27 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** autologous mesenchymal stem cells

## Key facts

- **NCT ID:** NCT01609283
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01609283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01609283, "A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01609283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*